{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:45:29Z","timestamp":1780361129482,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:00:00Z","timestamp":1558137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:00:00Z","timestamp":1558137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00277-019-03686-y","type":"journal-article","created":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T15:13:49Z","timestamp":1558278829000},"page":"1665-1674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Interim PET-CT\u2013guided therapy in elderly patients with Hodgkin lymphoma\u2014a retrospective national multi-center study"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5976-7121","authenticated-orcid":false,"given":"O. S.","family":"Bentur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Dann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Paran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Nachmias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gutwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Herishanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sarid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chava","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,18]]},"reference":[{"key":"3686_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s11899-011-0089-7","volume":"6","author":"TV Halbsguth","year":"2011","unstructured":"Halbsguth TV, B\u00f6ll B, Borchmann P, Diehl V (2011) The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma. Curr Hematol Malig Rep 6:164\u2013171. \n                    https:\/\/doi.org\/10.1007\/s11899-011-0089-7","journal-title":"Curr Hematol Malig Rep"},{"key":"3686_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.critrevonc.2008.12.007","volume":"71","author":"SJ Proctor","year":"2009","unstructured":"Proctor SJ, Wilkinson J, Sieniawski M (2009) Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol 71:222\u2013232. \n                    https:\/\/doi.org\/10.1016\/j.critrevonc.2008.12.007","journal-title":"Crit Rev Oncol Hematol"},{"key":"3686_CR3","unstructured":"Ries LA, Kosary CL, Hankey BF (1997) SEER cancer statistics review, 1973-1994, National Cancer Institute. NIH Pub. No. 97-2789. . Bethesda"},{"key":"3686_CR4","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","volume":"30","author":"AA Moccia","year":"2012","unstructured":"Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Shenkier TN, Slack GW, Skinnider B, Gascoyne RD, Connors JM, Sehn LH (2012) International prognostic score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era. J Clin Oncol 30:3383\u20133388. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.41.0910","journal-title":"J Clin Oncol"},{"key":"3686_CR5","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","volume":"24","author":"B Klimm","year":"2013","unstructured":"Klimm B, Goergen H, Fuchs M, von Tresckow B, B\u00f6ll B, Meissner J, Glunz A, Diehl V, Eich HT, Engert A, Borchmann P (2013) Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions. Ann Oncol 24:3070\u20133076. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdt413","journal-title":"Ann Oncol"},{"key":"3686_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","volume":"30","author":"B von Tresckow","year":"2012","unstructured":"von Tresckow B, Pl\u00fctschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A (2012) Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30:907\u2013913. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.38.5807","journal-title":"J Clin Oncol"},{"key":"3686_CR7","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","volume":"27","author":"A Engert","year":"2009","unstructured":"Engert A, Diehl V, Franklin J, Lohri A, D\u00f6rken B, Ludwig WD, Koch P, H\u00e4nel M, Pfreundschuh M, Wilhelm M, Tr\u00fcmper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, M\u00fcller-Hermelink HK, Hasenclever D, L\u00f6ffler M (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548\u20134554. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.19.8820","journal-title":"J Clin Oncol"},{"key":"3686_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.7326\/0003-4819-100-1-13","volume":"100","author":"MM Austin-Seymour","year":"1984","unstructured":"Austin-Seymour MM (1984) Hodgkin\u2019s disease in patients over sixty years old. Ann Intern Med 100:13. \n                    https:\/\/doi.org\/10.7326\/0003-4819-100-1-13","journal-title":"Ann Intern Med"},{"key":"3686_CR9","first-page":"889","volume":"66","author":"BA Peterson","year":"1982","unstructured":"Peterson BA, Pajak TF, Cooper MR, Nissen NI, Glidewell OJ, Holland JF, Bloomfield CD, Gottlieb AJ (1982) Effect of age on therapeutic response and survival in advanced Hodgkin\u2019s disease. Cancer Treat Rep 66:889\u2013898","journal-title":"Cancer Treat Rep"},{"key":"3686_CR10","first-page":"463","volume":"74","author":"A Bosi","year":"1989","unstructured":"Bosi A, Ponticelli P, Casini C, Messori A, Bellesi G, Biti G, Cionini L, Longo G, Mungai V, Rossi Ferrini P (1989) Clinical data and therapeutic approach in elderly patients with Hodgkin\u2019s disease. Haematologica 74:463\u2013473","journal-title":"Haematologica"},{"key":"3686_CR11","volume-title":"Cancer","author":"FL Erdkamp","year":"1992","unstructured":"Erdkamp FL, Breed WP, Bosch LJ et al (1992) Hodgkin disease in the elderly. A registry-based analysis. In: Cancer"},{"key":"3686_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/oxfordjournals.annonc.a057939","volume":"2","author":"G Enblad","year":"1991","unstructured":"Enblad G, Glimelius B, Sundstr\u00f6m C (1991) Original article: treatment outcome in Hodgkin\u2019s disease in patients above the age of 60: a population-based study. Ann Oncol 2:297\u2013302. \n                    https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a057939","journal-title":"Ann Oncol"},{"key":"3686_CR13","first-page":"46","volume":"79","author":"A Levis","year":"1994","unstructured":"Levis A, Depaoli L, Urgesi A, Bertini M, Orsucci L, Vitolo U, Buchi G, Gallamini A, Gavarotti P, Novarino A, Rota Scalabrini D, Mazza U, Pileri A, Sannazzari GL, Resegotti L (1994) Probability of cure in elderly Hodgkin\u2019s disease patients. Haematologica 79:46\u201354","journal-title":"Haematologica"},{"key":"3686_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1200\/JCO.2002.20.4.1087","volume":"20","author":"CD Weekes","year":"2002","unstructured":"Weekes CD, Vose JM, Lynch JC, Weisenburger DD, Bierman PJ, Greiner T, Bociek G, Enke C, Bast M, Chan WC, Armitage JO, Nebraska Lymphoma Study Group (2002) Hodgkin\u2019s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 20:1087\u20131093. \n                    https:\/\/doi.org\/10.1200\/JCO.2002.20.4.1087","journal-title":"J Clin Oncol"},{"key":"3686_CR15","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/10428190290033332","volume":"43","author":"N Macpherson","year":"2002","unstructured":"Macpherson N, Klasa RJ, Gascoyne R, O\u2019Reilly SE, Voss N, Connors JM (2002) Treatment of elderly Hodgkin\u2019s lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. Leuk Lymphoma 43:1395\u20131402. \n                    https:\/\/doi.org\/10.1080\/10428190290033332","journal-title":"Leuk Lymphoma"},{"key":"3686_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0360-3016(02)04596-0","volume":"56","author":"HK Kim","year":"2003","unstructured":"Kim HK, Silver B, Li S, Neuberg D, Mauch P (2003) Hodgkin\u2019s disease in elderly patients (> or =60): clinical outcome and treatment strategies. Int J Radiat Oncol Biol Phys 56:556\u2013560","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3686_CR17","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1200\/JCO.2012.47.3058","volume":"31","author":"AM Evens","year":"2013","unstructured":"Evens AM, Hong F (2013) How can outcomes be improved for older patients with Hodgkin lymphoma? J Clin Oncol 31:1502\u20131505. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.47.3058","journal-title":"J Clin Oncol"},{"key":"3686_CR18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","volume":"119","author":"AM Evens","year":"2012","unstructured":"Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM (2012) A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 119:692\u2013695. \n                    https:\/\/doi.org\/10.1182\/blood-2011-09-378414","journal-title":"Blood"},{"key":"3686_CR19","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1007\/s00259-010-1490-5","volume":"37","author":"SF Barrington","year":"2010","unstructured":"Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, Almquist H, Loft A, H\u00f8jgaard L, Federico M, Gallamini A, Smith P, Johnson P, Radford J, O\u2019Doherty MJ (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:1824\u20131833. \n                    https:\/\/doi.org\/10.1007\/s00259-010-1490-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3686_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/bjh.12878","volume":"166","author":"GA Follows","year":"2014","unstructured":"Follows GA, Ardeshna KM, Barrington SF, Culligan DJ, Hoskin PJ, Linch D, Sadullah S, Williams MV, Wimperis JZ, The British Committee for Standards in Haematology (2014) Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol 166:34\u201349. \n                    https:\/\/doi.org\/10.1111\/bjh.12878","journal-title":"Br J Haematol"},{"key":"3686_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer\/Dutch Hemato-Oncology Group, Grupo Espa\u00f1ol de M\u00e9dula \u00d3sea, German High-Grade Lymphoma Study Group, German Hodgkin\u2019s Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"3686_CR22","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","volume":"32","author":"JMM Raemaekers","year":"2014","unstructured":"Raemaekers JMM, Andr\u00e9 MPE, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Ferm\u00e9 C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van Imhoff G, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C (2014) Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 32:1188\u20131194. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.51.9298","journal-title":"J Clin Oncol"},{"key":"3686_CR23","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O\u2019Doherty M, Barrington S (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 372:1598\u20131607. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1408648","journal-title":"N Engl J Med"},{"key":"3686_CR24","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, di Raimondo F, D\u2019Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746\u20133752. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.11.6525","journal-title":"J Clin Oncol"},{"key":"3686_CR25","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1200\/JCO.2007.11.9867","volume":"25","author":"R Advani","year":"2007","unstructured":"Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ (2007) Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin\u2019s disease. J Clin Oncol 25:3902\u20133907. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.11.9867","journal-title":"J Clin Oncol"},{"key":"3686_CR26","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A, d\u2019Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O\u2019Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 374:2419\u20132429. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1510093","journal-title":"N Engl J Med"},{"key":"3686_CR27","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","volume":"34","author":"OW Press","year":"2016","unstructured":"Press OW, Li H, Sch\u00f6der H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW (2016) US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim Fluorodeoxyglucose-positron emission tomography imaging: southwest oncology group S0816. J Clin Oncol 34:2020\u20132027. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.63.1119","journal-title":"J Clin Oncol"},{"key":"3686_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1182\/blood-2006-04-019901","volume":"109","author":"EJ Dann","year":"2007","unstructured":"Dann EJ, Bar-Shalom R, Tamir A, Haim N, Ben-Shachar M, Avivi I, Zuckerman T, Kirschbaum M, Goor O, Libster D, Rowe JM, Epelbaum R (2007) Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 109:905\u2013909. \n                    https:\/\/doi.org\/10.1182\/blood-2006-04-019901","journal-title":"Blood"},{"key":"3686_CR29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bjh.14734","volume":"178","author":"EJ Dann","year":"2017","unstructured":"Dann EJ, Bairey O, Bar-Shalom R, Mashiach T, Barzilai E, Kornberg A, Akria L, Tadmor T, Filanovsky K, Abadi U, Kagna O, Ruchlemer R, Abdah-Bortnyak R, Goldschmidt N, Epelbaum R, Horowitz NA, Lavie D, Ben-Yehuda D, Shpilberg O, Paltiel O (2017) Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET\/CT is beneficial: a prospective multicentre trial of 355 patients. Br J Haematol 178:709\u2013718. \n                    https:\/\/doi.org\/10.1111\/bjh.14734","journal-title":"Br J Haematol"},{"key":"3686_CR30","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","volume":"23","author":"A Engert","year":"2005","unstructured":"Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, D\u00fchmke E, M\u00fcller-Hermelink K, Diehl V (2005) Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group. J Clin Oncol 23:5052\u20135060. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.11.080","journal-title":"J Clin Oncol"},{"key":"3686_CR31","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","volume":"31","author":"B B\u00f6ll","year":"2013","unstructured":"B\u00f6ll B, G\u00f6rgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghan\u00df C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P (2013) ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 31:1522\u20131529. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.45.4181","journal-title":"J Clin Oncol"},{"key":"3686_CR32","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease. N Engl J Med 339:1506\u20131514. \n                    https:\/\/doi.org\/10.1056\/NEJM199811193392104","journal-title":"N Engl J Med"},{"key":"3686_CR33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.12222","volume":"161","author":"AM Evens","year":"2013","unstructured":"Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Gospodarowicz M, Cheson BD, Stiff PJ, Advani R, Miller TP, Hoppe RT, Kahl BS, Horning SJ (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 161:76\u201386. \n                    https:\/\/doi.org\/10.1111\/bjh.12222","journal-title":"Br J Haematol"},{"key":"3686_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pupt.2005.01.007","volume":"18","author":"E Azambuja","year":"2005","unstructured":"Azambuja E, Fleck JF, Batista RG, Menna Barreto SS (2005) Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther 18:363\u2013366. \n                    https:\/\/doi.org\/10.1016\/j.pupt.2005.01.007","journal-title":"Pulm Pharmacol Ther"},{"key":"3686_CR35","first-page":"438","volume":"88","author":"O Landgren","year":"2003","unstructured":"Landgren O, Algernon C, Axdorph U, Nilsson B, Wedelin C, Porwit-MacDonald A, Grimfors G, Bj\u00f6rkholm M (2003) Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88:438\u2013444","journal-title":"Haematologica"},{"key":"3686_CR36","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/annonc\/mdi023","volume":"16","author":"V Ballova","year":"2005","unstructured":"Ballova V, R\u00fcffer JU, Haverkamp H, Pfistner B, M\u00fcller-Hermelink HK, D\u00fchmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, L\u00f6ffler M, Diehl V, Engert A (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16:124\u2013131. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdi023","journal-title":"Ann Oncol"},{"key":"3686_CR37","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","volume":"127","author":"B B\u00f6ll","year":"2016","unstructured":"B\u00f6ll B, Goergen H, Behringer K et al (2016) Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 127:2189\u20132192. \n                    https:\/\/doi.org\/10.1182\/blood-2015-11-681064","journal-title":"Blood"},{"key":"3686_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/annonc\/mdh012","volume":"15","author":"A Levis","year":"2004","unstructured":"Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, Vitolo U, Angelucci E, Boccadoro M, Gallo E, Mandelli F, Intergruppo Italiano Linfomi (IIL) (2004) VEPEMB in elderly Hodgkin\u2019s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol 15:123\u2013128","journal-title":"Ann Oncol"},{"key":"3686_CR39","doi-asserted-by":"publisher","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","volume":"119","author":"SJ Proctor","year":"2012","unstructured":"Proctor SJ, Wilkinson J, Jones G, Watson GC, Lucraft HH, Mainou-Fowler T, Culligan D, Galloway MJ, Wood KM, McNally RJQ, James PW, Goodlad JR (2012) Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood 119:6005\u20136015. \n                    https:\/\/doi.org\/10.1182\/blood-2011-12-396556","journal-title":"Blood"},{"key":"3686_CR40","first-page":"450","volume":"81","author":"A Levis","year":"1996","unstructured":"Levis A, Depaoli L, Bertini M et al (1996) Results of a low aggressivity chemotherapy regimen (CVP\/CEB) in elderly Hodgkin\u2019s disease patients. Haematologica 81:450\u2013456","journal-title":"Haematologica"},{"key":"3686_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hon.2900130104","volume":"13","author":"JR Diaz-Pavon","year":"1995","unstructured":"Diaz-Pavon JR, Cabanillas F, Majlis A, Hagemeister FB (1995) Outcome of Hodgkin\u2019s disease in elderly patients. Hematol Oncol 13:19\u201327","journal-title":"Hematol Oncol"},{"key":"3686_CR42","volume-title":"IARC Press","author":"S Swerdlow","year":"2008","unstructured":"Swerdlow S, Campo E, Harris N (2008) WHO classification of hematopoietic and lymphoidtissues. In: IARC Press. Lyon, France"},{"key":"3686_CR43","volume-title":"IARC Press","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H (2001) World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: IARC Press. Lyon, France"},{"key":"3686_CR44","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","volume":"28","author":"HT Eich","year":"2010","unstructured":"Eich HT, Diehl V, G\u00f6rgen H, Pabst T, Markova J, Debus J, Ho A, D\u00f6rken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, D\u00f6hner H, Borchmann P, M\u00fcller-Hermelink HK, M\u00fcller RP, Engert A (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28:4199\u20134206. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.29.8018","journal-title":"J Clin Oncol"},{"key":"3686_CR45","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","volume":"18","author":"DA Eichenauer","year":"2017","unstructured":"Eichenauer DA, Pl\u00fctschow A, Kreissl S, S\u00f6kler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P (2017) Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin study group. Lancet Oncol 18:1680\u20131687. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30696-4","journal-title":"Lancet Oncol"},{"key":"3686_CR46","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1097-0142(19840301)53:5<1202::AID-CNCR2820530530>3.0.CO;2-L","volume":"53","author":"C Wedelin","year":"1984","unstructured":"Wedelin C, Bj\u00f6rkholm M, Biberfeld P, Holm G, Johansson B, Mellstedt H (1984) Prognostic factors in Hodgkin\u2019s disease with special reference to age. Cancer 53:1202\u20131208","journal-title":"Cancer"},{"key":"3686_CR47","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Ill\u00e9s \u00c1, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, ECHELON-1 Study Group (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 378:331\u2013344. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1708984","journal-title":"N Engl J Med"},{"key":"3686_CR48","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"3686_CR49","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","volume":"385","author":"K Behringer","year":"2015","unstructured":"Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, B\u00f6ll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385:1418\u20131427. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)61469-0","journal-title":"Lancet"},{"key":"3686_CR50","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Ferm\u00e9 C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 35:1786\u20131794. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.68.6394","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03686-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03686-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03686-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T23:24:00Z","timestamp":1589671440000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03686-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,18]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3686"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03686-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,18]]},"assertion":[{"value":"9 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}}]}}